Clinical Trial Update: The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma [Phase 2]

View source ↗

Summary

Phase 2 study of MT027 allogeneic CAR-T for recurrent glioblastoma (IDH-wildtype) is not yet recruiting, per the trial update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• MT027 Allogeneic CAR-T (MT027 CAR-T)

Snippet

Sponsor: T-MAXIMUM Pharmaceutical Inc | Conditions: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Phase 2 | Status: NOT_YET_RECRUITING